News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
415,294 Results
Type
Article (33874)
Company Profile (67)
Press Release (381346)
Multimedia
Podcasts (75)
Webinars (8)
Section
Business (115295)
Career Advice (1381)
Deals (24319)
Drug Delivery (106)
Drug Development (60416)
Employer Resources (111)
FDA (10280)
Job Trends (9266)
News (215207)
Policy (25834)
Tag
Academia (1866)
Accelerated approval (21)
Adcomms (25)
Allergies (99)
Alliances (42532)
ALS (114)
Alzheimer's disease (1313)
Antibody-drug conjugate (ADC) (213)
Approvals (10351)
Artificial intelligence (311)
Autoimmune disease (72)
Automation (17)
Bankruptcy (239)
Best Places to Work (7762)
BIOSECURE Act (16)
Biosimilars (140)
Biotechnology (43)
Bladder cancer (102)
Brain cancer (53)
Breast cancer (399)
Cancer (3259)
Cardiovascular disease (260)
Career advice (1169)
Career pathing (24)
CAR-T (184)
CDC (53)
Cell therapy (486)
Cervical cancer (25)
Clinical research (50773)
Collaboration (1211)
Company closure (3)
Compensation (876)
Complete response letters (47)
COVID-19 (2592)
CRISPR (60)
C-suite (369)
Cystic fibrosis (81)
Data (4035)
Decentralized trials (1)
Denatured (11)
Depression (89)
Diabetes (357)
Diagnostics (3712)
Digital health (21)
Diversity (7)
Diversity, equity & inclusion (35)
Drug discovery (158)
Drug pricing (168)
Drug shortages (31)
Duchenne muscular dystrophy (179)
Earnings (42860)
Editorial (53)
Employer branding (18)
Employer resources (103)
Events (48568)
Executive appointments (464)
FDA (12244)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (5)
Frontotemporal dementia (15)
Funding (865)
Gene editing (129)
Generative AI (30)
Gene therapy (423)
GLP-1 (895)
Government (4365)
Grass and pollen (6)
Guidances (297)
Healthcare (11531)
HIV (45)
Huntington's disease (35)
IgA nephropathy (64)
Immunology and inflammation (171)
Immuno-oncology (29)
Indications (54)
Infectious disease (2830)
Inflammatory bowel disease (108)
Inflation Reduction Act (11)
Influenza (100)
Intellectual property (136)
Interviews (244)
IPO (10583)
IRA (46)
Job creations (1827)
Job search strategy (994)
Kidney cancer (10)
Labor market (50)
Layoffs (366)
Leadership (19)
Legal (7121)
Liver cancer (63)
Longevity (12)
Lung cancer (468)
Lymphoma (269)
Machine learning (32)
Management (33)
Manufacturing (486)
MASH (128)
Medical device (6067)
Medtech (6088)
Mergers & acquisitions (14504)
Metabolic disorders (978)
Multiple sclerosis (100)
NASH (20)
Neurodegenerative disease (214)
Neuropsychiatric disorders (58)
Neuroscience (2120)
NextGen: Class of 2025 (3741)
Non-profit (2806)
Now hiring (11)
Obesity (499)
Opinion (243)
Ovarian cancer (98)
Pain (101)
Pancreatic cancer (157)
Parkinson's disease (193)
Partnered (21)
Patents (286)
Patient recruitment (234)
Peanut (42)
People (27089)
Pharmaceutical (20)
Pharmacy benefit managers (18)
Phase I (15358)
Phase II (22058)
Phase III (17909)
Pipeline (2836)
Policy (260)
Postmarket research (1863)
Preclinical (6404)
Press Release (28)
Prostate cancer (166)
Psychedelics (39)
Radiopharmaceuticals (226)
Rare diseases (537)
Real estate (2656)
Recruiting (49)
Regulatory (17555)
Reports (24)
Research institute (1639)
Resumes & cover letters (210)
Rett syndrome (22)
RNA editing (8)
RSV (77)
Schizophrenia (111)
Series A (121)
Series B (97)
Service/supplier (4)
Sickle cell disease (56)
Special edition (12)
Spinal muscular atrophy (148)
Sponsored (26)
Startups (2016)
State (1)
Stomach cancer (12)
Supply chain (77)
Tariffs (80)
The Weekly (63)
Vaccines (977)
Venture capital (57)
Weight loss (352)
Women's health (41)
Worklife (10)
Date
Today (71)
Last 7 days (441)
Last 30 days (1719)
Last 365 days (20107)
2025 (19520)
2024 (22584)
2023 (25478)
2022 (33712)
2021 (36283)
2020 (34396)
2019 (28268)
2018 (21535)
2017 (20523)
2016 (18928)
2015 (21726)
2014 (16137)
2013 (12995)
2012 (13786)
2011 (14549)
2010 (13211)
Location
Africa (597)
Alabama (47)
Alaska (3)
Arizona (113)
Arkansas (5)
Asia (27057)
Australia (4841)
California (6338)
Canada (1922)
China (694)
Colorado (253)
Connecticut (287)
Delaware (221)
Europe (65195)
Florida (949)
Georgia (209)
Hawaii (3)
Idaho (30)
Illinois (451)
India (41)
Indiana (321)
Iowa (16)
Japan (290)
Kansas (76)
Kentucky (22)
Louisiana (16)
Maine (32)
Maryland (930)
Massachusetts (4533)
Michigan (153)
Minnesota (222)
Mississippi (1)
Missouri (73)
Montana (21)
Nebraska (10)
Nevada (68)
New Hampshire (29)
New Jersey (1935)
New Mexico (16)
New York (1827)
North Carolina (779)
North Dakota (5)
Northern California (3129)
Ohio (179)
Oklahoma (9)
Oregon (11)
Pennsylvania (1284)
Puerto Rico (9)
Rhode Island (16)
South America (817)
South Carolina (32)
South Dakota (1)
Southern California (2428)
Tennessee (81)
Texas (820)
United States (22550)
Utah (147)
Vermont (1)
Virginia (161)
Washington D.C. (44)
Washington State (484)
West Virginia (2)
Wisconsin (53)
Wyoming (2)
415,294 Results for "novartis ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
October 27, 2025
·
13 min read
Press Releases
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
September 9, 2025
·
10 min read
Clinical Research
Terns Climbs 10% As ‘Unprecedented’ Leukemia Data Beats Novartis’ Scemblix
TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech’s shares flying.
December 9, 2025
·
3 min read
·
Annalee Armstrong
Radiopharmaceuticals
Novartis’ Pluvicto Heavywork Proves Radiopharma Can Succeed
While investment has slowed in radiopharmaceuticals, analysts predict increased interest to come as Novartis shows just how successful radiopharmaceuticals can be.
November 6, 2025
·
5 min read
·
Annalee Armstrong
Approvals
Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight
The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access to patients two years and older in what one Stanford Medicine professor called a “game changing advance” for the field.
November 25, 2025
·
3 min read
·
Heather McKenzie
Mergers & acquisitions
Avidity Played Hardball To Land Favorable Terms in $12B Novartis Deal
At one point in merger negotiations with Novartis, Avidity CEO Sarah Boyce and her team walked, cutting off access to a data room and moving on to a capital raise.
November 25, 2025
·
3 min read
·
Annalee Armstrong
Podcast
Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; Novartis’ CEO also downplayed the impact of Big Pharma pricing deals with the Trump administration; Regeneron continued the trend of dropping cell therapy assets;
BioSpace
takes a look at how the FDA is functioning mid-shutdown.
October 29, 2025
·
1 min read
·
Heather McKenzie
Mergers & acquisitions
Novartis Deals in Cardio Again, Dropping $1.4B To Acquire Tourmaline
Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ProFound Therapeutics and China’s Argo Biopharmaceutical, among others.
September 9, 2025
·
2 min read
·
Tristan Manalac
Earnings
Novartis CEO Says Trump’s Drug Pricing Deals Don’t Address Root Problem
Vas Narasimhan confirmed that Novartis is having weekly discussions with the Trump administration on drug pricing, but a deal has not yet been reached.
October 28, 2025
·
3 min read
·
Annalee Armstrong
M&A
Novartis To ‘Bolster’ Neuromuscular Pipeline With $12B Avidity Acquisition
The deal, announced early Sunday afternoon, will see Novartis gain access to Avidity’s neuroscience assets, while the San Diego biotech spins out a new company to shepherd its early-stage precision cardiology programs.
October 26, 2025
·
2 min read
·
Heather McKenzie
1 of 41,530
Next